Table 3. Hepatic and inflammatory marker values in healthy subjects, and patients after four months of Omegaven® treatment, and patients with chronic ClinOleic®, Lipofundin® and SMOFlipid® based-home parenteral nutrition. *p<0.05 vs. values of healthy and Omegaven®.
| Healthy subjects (n = 6) | Omegaven® (n = 2) | ClinOleic® ((n = 4) | Lipofundin® (n = 1) | SMOFlipid® (n = 3) | |
| AST (11–39 IU/L) | 22±4.2 | 27.5±6.3 | 83±25.8* | 57* | 44±9.5* |
| ALT (7–33 IU/L | 19±2.1 | 30.5±1.9 | 152.3±52.3* | 52* | 70.3±17.6* |
| GGT (8–55 IU/L) | 27±6.2 | 35.5±19 | 64.7±40.7 * | 127* | 62±28.6* |
| Alkaline phosphatase (50–300 IU/L) | 69±2.4 | 113.5±7.7 | 140.5±36.4* | 111 | 127.3±24.5 |
| Total bilirubin (<2.5 mg/dL) | 0.5±0.1 | 0.8±0.3 | 0.6±0.12 | 0.9 | 0.6±0.4 |
| Prealbumin. (18–45 mg/dL) | 22.4±0.3 | 21.4±0.9 | 20±1.5 | 18 | 21.9±2.2 |
| Serum albumin. (3.2–5.2 g/dL) | 4.1±0.1 | 3.8±0.14 | 3.8±0.15 | 3.5 | 3.5±0.15 |
| Total protein. g/dL | 7.1±1.1 | 7.1±0.21 | 6.7±0.2 | 7 | 6.6±0.8 |
| Platelets (135–350 cells 109/L) | 213±69 | 176±18.3 | 162.3±9.6 | 104 | 217±72 |
| Hemoglobin (13.5–18 g/dL) | 16.2±1.3 | 13.2±0.1 | 13.8±0.4 | 12.5 | 13.5±0.6 |
| Leukocytes (5–1010cells/L) | 6.5±0.2 | 5.9±2.3 | 6±0.8 | 4.7 | 9.3±3.4 |
| Neutrophils % | 52±3.1 | 35.8±5* | 58.6±10.7 | 68 | 61.3±11.3 |
| Lymphcytes % | 34±0.1 | 49.3±8.2* | 24.7±0.8 | 18 | 24±10.1 |
| Monocytes % | 7.2±0.4 | 9.5±0.3 | 15.2±0.4 | 16.3 | 14.6±0.1 |
| MMP9 (pg/mL) | 112.1±19.3 | 96±26.9 | 825.5±214.6* | 476.7* | 771.2±367.9* |
| TGFβ1(ng/mL) | 11.2±1.1 | 8.7±2 | 40.1±11.8* | 34.3* | 34.8±3.8* |
| TNFα (pg/mL) | 138.4±13.4 | 102.2±14.3 | 526.6±143.8* | 598.1* | 513.8±114.9* |
| IL1β (pg/mL) | 7.1±1.2 | 6.6±0.4 | 28.2±13.4* | 41.2* | 38.1±5.2* |
| IL-8 (pg/mL) | 41.6±3.2 | 42.9±4.8 | 443.8±94.5* | 491.2* | 356.6±53.1* |
| IL-6 (pg/mL) | 7.4±0.6 | 5.1±0.26 | 25.6±5.6* | 37.1* | 23.1±1.7* |